Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy

BACKGROUND: Multidrug resistance is responsible for the poor outcome in breast cancer therapy. Lapa is a novel therapeutic agent that generates ROS through the catalysis of the NAD(P) H:quinone oxidoreductase-1 (NQO1) enzyme which significantly facilitate the intracellular accumulation of the co-del...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Jia, Xiaoqian, Niu, Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047616/
https://www.ncbi.nlm.nih.gov/pubmed/30034236
http://dx.doi.org/10.2147/IJN.S163929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047616/
https://www.ncbi.nlm.nih.gov/pubmed/30034236
http://dx.doi.org/10.2147/IJN.S163929

Ejemplares similares